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ABSTRACT
Objectives: We evaluated the hypothesis that cyclooxygenase (COX) inhibitor use might have
counteracted a beneficial effect of postmenopausal hormone therapy, and account for the
absence of cardioprotection in the Women’s Health Initiative hormone trials. Estrogen increases
COX expression, and inhibitors of COX such as nonsteroidal anti-inflammatory agents appear to
increase coronary risk, raising the possibility of a clinically important interaction in the trials.
Design: The hormone trials were randomized, double-blind, and placebo-controlled. Use of
nonsteroidal anti-inflammatory drugs was assessed at baseline and at years 1, 3, and 6.
Setting: The Women’s Health Initiative hormone trials were conducted at 40 clinical sites in
the United States.
Participants: The trials enrolled 27,347 postmenopausal women, aged 50–79 y.
Interventions: We randomized 16,608 women with intact uterus to conjugated estrogens
0.625 mg with medroxyprogesterone acetate 2.5 mg daily or to placebo, and 10,739 women
with prior hysterectomy to conjugated estrogens 0.625 mg daily or placebo.
Outcome Measures: Myocardial infarction, coronary death, and coronary revascularization
were ascertained during 5.6 y of follow-up in the estrogen plus progestin trial and 6.8 y of
follow-up in the estrogen alone trial.
Results: Hazard ratios with 95% confidence intervals were calculated from Cox proportional
hazard models stratified by COX inhibitor use. The hazard ratio for myocardial infarction/
coronary death with estrogen plus progestin was 1.13 (95% confidence interval 0.68–1.89)
among non-users of COX inhibitors, and 1.35 (95% confidence interval 0.86–2.10) among
continuous users. The hazard ratio with estrogen alone was 0.92 (95% confidence interval 0.57–
1.48) among non-users of COX inhibitors, and 1.08 (95% confidence interval 0.69–1.70) among
continuous users. In a second analytic approach, hazard ratios were calculated from Cox
models that included hormone trial assignment as well as a time-dependent covariate for
medication use, and an interaction term. No significant interaction was identified.
Conclusions: Use of COX inhibitors did not significantly affect the Women’s Health Initiative
hormone trial results. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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PLoS CLINICAL TRIALSINTRODUCTION
The relationship between cyclooxygenase (COX) inhibition
and coronary heart disease (CHD) risk is currently the focus
of intense scrutiny [1,2]. The putative increase in CHD risk
with selective COX-2 inhibitors has been attributed to
reduction in atheroprotective prostacyclin I2 levels [3].
Estrogen activates COX-2 in female mice through an estro-
gen-receptor-mediated mechanism, thereby increasing levels
of prostacyclin [4]. This observation has raised concern that
COX inhibition might counteract a beneﬁcial effect of
estrogen on prostacyclin levels and, in fact, account for the
absence of cardioprotection with estrogen in recent random-
ized trials [5].
Mammals have two isoforms of COX. COX-1 is expressed in
most tissues and mediates activities such as vascular homeo-
stasis and gastroprotection [6]. COX-2 is induced at sites of
inﬂammation and mediates inﬂammatory responses [7],
making its blockade a target for treatment of arthritis and
postoperative pain. Low-dose aspirin inhibits COX-1 [8],
traditional nonsteroidal anti-inﬂammatory drugs (NSAIDs)
inhibit COX  1a n dC O X - 2[ 9 ] ,a n ds e l e c t i v eC O X - 2
inhibitors such as rofecoxib, celecoxib, and valdecoxib
selectively inhibit COX-2 [10].
The Women’s Health Initiative hormone trials unexpect-
edly demonstrated no overall reduction in coronary risk [11],
and a suggestion of harm with combination estrogen with
progestin [12]. This analysis evaluates the hypothesis that
COX inhibition with NSAIDs modulated the effect of
postmenopausal hormone therapy on coronary risk in the
Women’s Health Initiative randomized hormone trials.
METHODS
The design, recruitment, randomization, data collection,
intervention, and outcomes ascertainment procedures for
the Women’s Health Initiative hormone trials, including
CONSORT diagrams, have been described in detail elsewhere
[13–16]. Also see Figure 1.
Participants and Interventions
Between November 1993 and October 1998, 16,608 post-
menopausal women, aged 50–79 y with intact uterus, were
randomized to conjugated estrogens 0.625 mg plus medrox-
yprogesterone acetate 2.5 mg daily (Prempro; Wyeth Phar-
maceuticals, Madison, New Jersey, United States) or placebo
in the estrogen plus progestin trial, and 10,739 women with
prior hysterectomy were randomized to conjugated estrogens
0.625 mg daily (Premarin; Wyeth Pharmaceuticals) or placebo
in the estrogen alone trial (Figure 1). The estrogen plus
progestin trial was stopped ahead of schedule after 5.6 y of
follow-up upon recommendation of the Data and Safety
Monitoring Board because of increased breast cancer risk
[16]; the estrogen alone trial was stopped ahead of schedule
after 6.8 y of follow-up by the National Institutes of Health
because of increased stroke risk and lack of cardioprotection
[17].
Figure 1. Women’s Health Initiative Hormone Trials
CEE, conjugated equine estrogens; MPA, medroxyprogesterone acetate.
DOI: 10.1371/journal.pctr.0010026.g001
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Estrogen, CHD Risk, and COX Inhibitors
Editorial Commentary
Background: As part of a set of studies known as the Women’s Health
Initiative trials, investigators aimed to find out whether providing
postmenopausal hormone therapy (estrogen in the case of women who
had had a hysterectomy, and estrogen plus progestin for women who
had not had a hysterectomy) reduced cardiovascular risk as compared to
placebo. Earlier observational studies had suggested this might be the
case. The trials found that postmenopausal hormone therapy did not
reduce cardiovascular risk in the groups studied. However, there was a
concern that medication use outside the trial with nonsteroidal anti-
inflammatory drugs (NSAIDs), and specifically the type of NSAID known
as COX-2 inhibitors, could have affected the findings. This concern arose
because it is known that COX-2 inhibition lowers levels of prostacyclin, a
molecule thought to be beneficial to cardiovascular health, whereas
estrogen increases prostacyclin levels. Evidence from randomized trials
and observational studies has also shown that patients treated with
some COX-2 inhibitors are at increased risk of heart attacks and strokes;
the cardiovascular safety of other NSAIDs is also the focus of great
attention. Therefore, the authors of this paper aimed to do a statistical
exploration of the data from the Women’s Health Initiative hormone
trials, to find out whether NSAID use by participants in the trials could
have affected the trials’ main findings.
What this trial shows: In this reanalysis of the original data from the
trials, the investigators found that the effects of hormone therapy on
cardiovascular outcomes were similar among users and non-users of
NSAIDs, confirming that use of these drugs did not significantly affect
the results from the Women’s Health Initiative hormone trials.
Strengths and limitations: The original hormone trials were large,
appropriately randomized studies that enrolled a diverse cohort of
participants. Therefore, a large number of cardiovascular events occurred
in the groups being compared, allowing this subsequent analysis to be
done. One limitation is that use of COX-2 inhibitors in the trial was low;
therefore, the investigators were not able to specifically test whether
COX-2 inhibitor use (as opposed to NSAID use generally) might have
affected their findings.
Contribution to the evidence: The investigators did not set out
specifically to evaluate the cardiovascular safety of particular medi-
cations in this study. Rather, they wanted to see if these NSAIDs could
have modified the effects of the hormone therapy. The secondary
analysis done here shows that the main findings from the Women’s
Health Initiative hormone trials were not significantly affected by use of
NSAIDs outside the trial.
The Editorial Commentary is written by PLoS staff, based on the reports of the
academic editors and peer reviewers.Outcomes
Medication use. Participants were asked to bring all medi-
cations, including prescription medications, over-the-counter
medications, vitamins, minerals, and bulk ﬁber supplements
to clinic for inventory at baseline and at years 1, 3, and 6.
Over-the-counter medications taken at least twice a week for
the preceding 2 wk, supplements taken at least once a week,
and all prescription medications were recorded. Aspirin use
indicates a dose of at least 80 mg taken at least twice weekly.
NSAIDs and selective COX-2 inhibitors were recorded
regardless of dose if they met the frequency of use criteria.
Continuous use indicates reported use at baseline and at each
follow-up inventory; some use indicates use at some, but not
all, medication inventories.
Clinical outcomes. Clinical outcomes were identiﬁed from
semiannual medical update questionnaires and conﬁrmed by
medical record review. CHD death and hospitalized myocar-
dial infarction were conﬁrmed by central adjudicators, the
latter using an algorithm that included symptoms, cardiac
enzymes, and electrocardiograms [18]. Coronary revasculari-
zation was conﬁrmed by centrally trained local adjudicators.
Statistical Methods
Cox proportional hazard models were stratiﬁed by age,
prevalent CHD, and randomization in the dietary modiﬁca-
tion trial [13], and adjusted for coronary revascularization at
baseline. The ﬁrst set of Cox models stratiﬁed participants by
NSAID use at baseline. The second set of models included a
main effect for randomization assignment in the hormone
trial and use of aspirin  80 mg daily, other NSAIDs, and
selective COX-2 inhibitors as time-dependent covariates, and
an interaction term. All reported p-values are two-sided.
Analyses were carried out by the coordinating center
statistics unit using the SAS system for Windows version 9
(SAS Institute, Cary, North Carolina, United States).
RESULTS
Adherence, follow-up, and clinical outcomes in the random-
ized trials have been previously reported [11,12,16,17].
Baseline Data
For the individual hormone trials, baseline characteristics
were balanced between the active intervention and placebo
groups [16,17]. Women with intact uterus in the estrogen plus
progestin trial had generally lower prevalence of CHD risk
factors than women with prior hysterectomy in the estrogen
alone trial (Table 1). For example, the average body mass
index of women in the estrogen plus progestin trial was 28.5
6 5.9 kg/m
2 compared with 30.1 6 6.2 kg/m
2 in the estrogen
alone trial. Prevalent hypertension was identiﬁed in 36.1%
versus 47.7% participants in the two trials, respectively, at
baseline, and self-reported diabetes mellitus requiring med-
ication was reported by 4.4% versus 7.7% of participants in
the two trials, respectively. The annualized rate percent of
myocardial infarction/CHD death was 0.56% for the placebo
group in the estrogen alone trial [11], compared with 0.33%
for the placebo group of the estrogen plus progestin trial [12].
Outcomes and Estimation
COX inhibitor use. Use of aspirin, traditional NSAIDs, and
selective COX-2 inhibitors is shown in Table 2. Among
women who used traditional NSAIDs in the estrogen alone
trial, 48% and 51% of those assigned to conjugated estrogens
and placebo, respectively, used ibuprofen alone (over-the-
counter or prescription), 16% and 17%, respectively, used
naproxen alone (over-the-counter or prescription), and 31%
and 29%, respectively, used other prescription NSAIDs. The
remainder took various combinations of ibuprofen, naprox-
en, and other prescription NSAIDs. Among women taking
NSAIDs in the estrogen plus progestin trial, 56% of women in
each treatment group took ibuprofen, while 14% of those
assigned to estrogen with progestin and 15% of those
assigned to placebo took naproxen. In each treatment group,
25% took other prescription NSAIDs.
Celecoxib and rofecoxib were approved by the Food and
Drug Administration in 1999, after completion of baseline
visits for the hormone trials. Consequently, no women were
taking selective COX-2 inhibitors at study entry. During the
course of the trial, a small proportion of women began taking
these agents.
.......................................................................................................................................................................................
Table 1. Baseline Characteristics of Hormone Trial Participants
Characteristic Subcategory Estrogen Plus Progestin Estrogen Alone
N 16,608 10,739
Age, years (mean 6 SD) 63.3 6 7.1 63.6 6 7.3
Body mass index, kg/m
2 (mean 6 SD) 28.5 6 5.4 30.1 6 6.2
Ethnicity White 13,945 (84.0) 8,082 (75.3)
Black 1,124 (6.8) 1,617 (15.1)
Hispanic 888 (5.3) 655 (6.1)
Asian/Pacific Islander 363 (2.2) 164 (1.5)
American Indian/Alaskan native 56 (0.3) 75 (0.7)
Other/not specified 232 (1.4) 146 (1.4)
Current smoker 1,718 (10.5) 1,113 (10.5)
Hypertension 4,537 (36.1) 3,896 (40.4)
Self-reported diabetes requiring drug treatment 734 (4.4) 821 (7.7)
Self-reported high cholesterol requiring pills 1,906 (12.7) 1,460 (15.2)
Prior myocardial infarction 296 (1.8) 337 (3.1)
Prior coronary revascularization 215 (1.3) 234 (2.2)
Values are n (percent) unless otherwise noted. Hypertension includes self-report of high blood pressure requiring pills and measured systolic blood pressure   140 mm Hg or diastolic
blood pressure   90 mm Hg.
SD, standard deviation.
DOI: 10.1371/journal.pctr.0010026.t001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Estrogen, CHD Risk, and COX InhibitorsRandomized hormone assignment and COX inhibitor use.
Hazard ratios and 95% conﬁdence intervals are shown for
coronary risk with randomized hormone assignment, strati-
ﬁed by NSAID use (Table 3). Among women reporting no
NSAID use, the hazard ratio for myocardial infarction/
coronary death was 1.13 (95% conﬁdence interval 0.68–
1.89) with estrogen plus progestin, and 0.92 (95% conﬁdence
interval 0.57–1.48) with unopposed estrogen. Among women
taking aspirin and/or other NSAIDs, conﬁdence intervals for
CHD risk were similar and spanned unity for both hormone
trials. For three strata (none, some, and continuous NSAID
use), the p-value for interaction with hormone assignment was
0.92 for estrogen with progestin and 0.82 for estrogen alone.
Similarly, for the composite outcome of myocardial
infarction/coronary death/coronary revascularization, the
hazard ratio among women reporting no NSAID use was
1.21 (95% conﬁdence interval 0.80–1.84) with estrogen plus
progestin, and 0.88 (95% conﬁdence interval 0.57–1.34) with
unopposed estrogen. For women taking NSAIDs, hazard
ratios were similar and 95% conﬁdence intervals for the
composite coronary outcome also spanned unity. For three
strata of NSAID use (none, some, and continuous), the p-value
for interaction with hormone assignment was 0.63 for
estrogen with progestin and 0.30 for estrogen alone.
A separate set of Cox models evaluating the risk of
myocardial infarction/coronary death or myocardial infarc-
tion/coronary death/coronary revascularization with NSAID
use included a main effect for randomization assignment in
the hormone trials, along with NSAID use as a time-dependent
covariate and an interaction term (Table 4). No signiﬁcant
interaction was identiﬁed between randomization assignment
and use of aspirin only, other NSAID only, NSAID with
aspirin, or NSAID without aspirin for either CHD outcome.
DISCUSSION
Interpretation
COX inhibitor use did not signiﬁcantly modulate the effect of
either unopposed conjugated estrogens or combined con-
jugated estrogens with medroxyprogesterone acetate on
coronary risk in the Women’s Health Initiative randomized
hormone trials. The effects of hormone therapy on risk of
coronary events were generally similar among users and non-
users of COX inhibitors, and no signiﬁcant interactions were
observed.
The strengths of our study include the systematic ascertain-
ment of clinical coronary outcomes, the large number of
CHD events, the randomized, placebo-controlled design, and
the periodic re-inventory of medications, permitting inclu-
sion of COX inhibitor use as a time-dependent covariate
(Table 4). Limitations include the fact that use of aspirin ,80
mg daily was not recorded, that only about 20% of women
were using NSAIDs, and that only a few percent used selective
COX-2 inhibitors. Thus, we were unable to adequately test
the possibilities that concurrent use of very low dose aspirin
or exclusive use of selective COX-2 inhibitors might modulate
CHD risk among women taking postmenopausal hormone
therapy. Further, the numbers of clinical events were small
for some categories of COX inhibitor use.
Generalizability
Characteristics of the Women’s Health Initiative hormone
trials include the large, diverse cohort and wide geographic
distribution of clinical sites. Each trial tested a single
regimen: when they were designed, the unopposed estrogen
and combination estrogen with progestin regimens were
selected because they were the most commonly prescribed
regimens in the United States.
Since observational studies of CHD risk with postmeno-
pausal hormone therapy provided misleading results [19],
determining the interaction between estrogen use and COX
inhibition would necessitate a factorial randomization to
estrogen or placebo and to COX inhibitor or placebo in a
population at sufﬁciently high CHD risk. Such a trial is
unlikely to be carried out, leaving the exploration of this issue
to studies using animal models, which have their own
limitations [20].
.......................................................................................................................................................................................
Table 2. Use of Aspirin, NSAIDs, and Selective COX-2 Inhibitors at Baseline and at Year 3
Drugs Used
a Time Point Estrogen Plus Progestin Estrogen Alone
Active Drug
(n ¼ 8,506)
Placebo
(n ¼ 8,102)
Active Drug
(n ¼ 5,310)
Placebo
(n ¼ 5,429)
Aspirin only Baseline 1,411 (17) 1,365 (17) 859 (16) 898 (17)
Year 3 1,452 (19) 1,473 (20) 912 (20) 935 (20)
NSAID only Baseline 1,227 (14) 1,198 (15) 936 (18) 957 (18)
Year 3 768 (10) 785 (11) 541 (12) 584 (12)
COX-2 only Baseline 0 (0) 0 (0) 0 (0) 0 (0)
Year 3 119 (2) 143 (2) 115 (2) 121 (3)
NSAID and aspirin Baseline 292 (3) 312 (4) 217 (4) 212 (4)
Year 3 244 (3) 222 (3) 133 (3) 163 (3)
NSAID or aspirin Baseline 2,930 (34) 2,875 (35) 2,012 (38) 2,067 (38)
Year 3 2,518 (33) 2,531 (35) 1,644 (35) 1,738 (36)
NSAID, COX-2, or aspirin Baseline 2,930 (34) 2,875 (35) 2,012 (38) 2,067 (38)
Year 3 2,637 (34) 2,674 (36) 1,759 (38) 1,859 (39)
Aspirin with or without NSAID/COX-2 Baseline 1,703 (20) 1,677 (21) 1,076 (20) 1,110 (20)
Year 3 1,741 (23) 1,739 (24) 1,095 (23) 1,150 (24)
Values are n (percent). Use at year 3 indicates medication use was reported at year 3, regardless of prior use.
aAspirin indicates  80 mg/d at least twice weekly. COX-2 indicates a selective COX-2 inhibitor.
DOI: 10.1371/journal.pctr.0010026.t002 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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This analysis is not intended to assess the coronary risk
associated with COX inhibitor use. Although we have more
complete information about over-the-counter NSAID use
and CHD risk characteristics, including physical activity and
diet, than some other epidemiologic analyses, this issue is best
examined in randomized trials [21–25] because of intrinsic
biases in COX inhibitor use related to patient selection and
treatment indications.
Iatrogenic imbalance between COX-1 and COX-2 activities
has been proposed as a mechanism underlying both favorable
and unfavorable cardiovascular effects of drugs [5,26]. COXs
synthesize prostacyclin I2 and thromboxane A2 from arach-
adonic acid. Prostacyclin I2, predominantly a product of
COX-2, is a vasodilator that inhibits platelet aggregation and
smooth muscle proliferation, effects that might be expected
to reduce acute coronary syndromes and stroke. Thrombox-
ane A2, produced by COX-1 in platelets, is a vasoconstrictor
that stimulates platelet aggregation, an effect that might be
expected to increase cardiovascular risk. Selective COX-2
inhibitors reduce prostacyclin without inhibiting production
of platelet-COX-1-derived thromboxane A2, a pharmacologic
effect that has been hypothesized to underlie the putative
adverse cardiovascular effects of these agents [24]. In contrast,
NSAIDs reduce formation of both prostacyclin and throm-
boxane A2, with individual drugs differing in their relative
blockade of COX-1 and COX-2 activities. Naproxen and
aspirin predominantly inhibit COX-1, whereas diclofenac,
etodolac, and meloxicam predominantly inhibit COX-2 [27].
Participants in the Women’s Health Initiative hormone trials
consumed a variety of NSAIDs, encompassing a range of
ratios of COX-1:COX-2 inhibition.
Estrogen increases expression of COX-2 and production of
prostacyclin I2, effects that have been proposed to underlie its
apparent cardioprotective effects in animal models [28].
Female low-density lipoprotein cholesterol receptor knock-
out mice developed more aortic plaque if they also lacked the
prostacyclin receptor; this phenomenon was not observed in
male mice. The prostacyclin-receptor-deﬁcient female mice
also demonstrated increased oxidative stress and platelet
.......................................................................................................................................................................................
Table 3. CHD Risk with Postmenopausal Hormone Therapy, Stratified by COX Inhibitor Use
Outcome Drug Use
a Estrogen Plus Progestin Estrogen Alone
n Number of Events Hazard
Ratio
(95% CI)
n Number of Events Hazard
Ratio
(95% CI)
Active
Drug
Group
Placebo
Group
Active
Drug
Group
Placebo
Group
MI/CHD death No aspirin, NSAID, COX-2 use 6,100 34 27 1.13 (0.68–1.89) 2,664 33 36 0.92 (0.57–1.48)
Some or continuous aspirin use,
no NSAID or COX-2
3,740 70 54 1.25 (0.87–1.79) 2,331 66 61 1.10 (0.78–1.56)
Continuous aspirin use, no NSAID
or COX-2
953 21 17 1.40 (0.73–2.69) 422 18 14 1.19 (0.59–2.42)
Some or continuous NSAID use,
no aspirin
2,855 17 15 1.07 (0.53–2.16) 1,824 18 17 1.08 (0.56–2.12)
Continuous NSAID or COX-2 use,
no aspirin
523 6 6 1.24 (0.37–4.10) 236 3 4 0.86 (0.15–4.88)
Continuous aspirin or NSAID use 2,367 44 35 1.35 (0.86–2.10) 1,260 39 40 1.08 (0.69–1.70)
No aspirin use, with or without
NSAID or COX-2
6,100 51 40 1.21 (0.80–1.84) 2,664 40 47 0.88 (0.57–1.34)
Some or continuous aspirin use,
with or without NSAID or COX-2
3,740 106 108 0.93 (0.71–1.21) 2,331 112 116 0.96 (0.74–1.25)
Continuous aspirin use, with or
without NSAID or COX-2
953 33 34 1.02 (0.62–1.66) 422 28 34 0.77 (0.46–1.30)
MI/CHD death/coronary
revascularization
No aspirin, NSAID, COX-2 use 6,100 51 40 1.21 (0.80–1.84) 2,664 40 47 0.88 (0.57–1.34)
Some or continuous aspirin use,
no NSAID or COX-2
3,740 106 108 0.93 (0.71–1.21) 2,331 112 116 0.96 (0.74–1.25)
Continuous aspirin use, no NSAID
or COX-2
953 33 34 1.02 (0.62–1.66) 422 28 34 0.77 (0.46–1.30)
Some or continuous NSAID use,
no aspirin
2,855 29 29 0.98 (0.58–1.66) 1,824 25 22 1.23 (0.69–2.20)
Continuous NSAID or COX-2 use,
no aspirin
523 11 8 1.67 (0.64–4.35) 236 3 4 0.86 (0.15–4.88)
Continuous aspirin or NSAID use 2,367 74 69 1.14 (0.82–1.58) 1,260 63 81 0.80 (0.58–1.13)
Some or continuous aspirin use,
with or without NSAID or COX-2
5,694 169 160 1.02 (0.82–1.27) 4,120 212 219 0.99 (0.82–1.20)
Continuous aspirin use, with or
without NSAID or COX-2
1,323 49 43 1.19 (0.78–1.80) 670 45 52 0.96 (0.63–1.45)
Cox models are shown for subgroups of women who did or did not use COX inhibitors. Continuous use indicates reported use at baseline and at each follow-up inventory. Some use
indicates reported use at some, but not all, medication inventories. Duration of follow-up was 5.2 y in the estrogen plus progestin trial and 6.8 y in the estrogen alone trial.
aAspirin indicates   80 mg/d at least twice weekly. COX-2 indicates selective COX-2 inhibitor.
CI, confidence interval; MI, myocardial infarction.
DOI: 10.1371/journal.pctr.0010026.t003 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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activation [4]. In cultured mouse aortic smooth muscle cells,
estrogen exposure increased COX-2 expression and prosta-
cyclin formation [4].
In view of these new ﬁndings and of the public health
impact of the Women’s Health Initiative hormone trials, we
felt it was important to assess any possible impact of COX
inhibitor use on the hormone trial results. Although this
analysis cannot conclusively determine whether exogenous
estrogen could ever modulate CHD risk with COX inhibition,
it does conﬁrm that use of COX inhibitors did not
signiﬁcantly affect the Women’s Health Initiative hormone
trial results.
SUPPORTING INFORMATION
CONSORT Checklist
Found at DOI: 10.1371/journal.pctr.0010026.sd001 (1.6 MB DOC).
Trial Protocol
Found at DOI: 10.1371/journal.pctr.0010026.sd002 (147 KB PDF).
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Table 4. CHD Risk with COX Inhibitor Use: Interaction with Randomized Hormone Assignment
Outcome Drug Use Estrogen Plus Progestin Estrogen Alone
Number of Events Hazard
Ratio
(95% CI)
p-Value
for
Interaction
Number of Events Hazard
Ratio
(95% CI)
p-Value
for
Interaction
Active Placebo Active Placebo
MI/CHD death No aspirin, NSAID, or COX-2 102 87 Referent 100 114 Referent
Aspirin only 50 32 1.11 (0.86–1.44) 0.143 55 54 1.08 (0.86–1.36) 0.505
NSAID or COX-2, no aspirin 25 17 1.10 (0.79–1.53) 0.470 20 29 1.06 (0.79–1.42) 0.475
Aspirin, NSAID, or COX-2 86 60 1.21 (0.97–1.51) 0.150 101 103 1.24 (1.01–1.51) 0.474
NSAID or COX-2, no aspirin 25 18 1.06 (0.77–1.46) 0.506 27 36 1.12 (0.86–1.46) 0.592
Aspirin, with or without
NSAID or COX-2
a
61 42 1.22 (0.96–1.56) 0.284 74 67 1.18 (0.95–1.47) 0.201
MI/CHD death/
revascularization
No aspirin, NSAID, or COX-2 154 140 Referent 190 183 Referent
Aspirin only 79 73 1.21 (1.00–1.48) 0.688 88 103 1.13 (0.95–1.34) 0.397
NSAID or COX-2, no aspirin 39 36 1.20 (0.94–1.54) 0.767 36 53 1.06 (0.85–1.32) 0.194
Aspirin, NSAID, or COX-2 140 131 1.42 (1.20–1.69) 0.676 166 189 1.23 (1.06–1.43) 0.318
NSAID or COX-2, no aspirin 41 39 1.20 (0.95–1.52) 0.782 46 62 1.07 (0.87–1.31) 0.283
Aspirin, with or without
NSAID or COX-2
a
99 92 1.38 (1.15–1.66) 0.794 120 127 1.22 (1.04–1.44) 0.892
COX models included a main effect for randomization assignment in the hormone trial, use of NSAIDs as a time-dependent covariate, and an interaction term.
aReferent group is no aspirin, with or without NSAID or selective COX-2 inhibitor.
CI, confidence interval; COX-2, selective COX-2 inhibitor; MI, myocardial infarction.
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